Format

Send to

Choose Destination
Vaccine. 2019 Jul 9;37(30):4103-4110. doi: 10.1016/j.vaccine.2019.05.075. Epub 2019 Jun 11.

Immune response and protective efficacy of the S particle presented rotavirus VP8* vaccine in mice.

Author information

1
Division of Infectious Diseases, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
2
Division of Infectious Diseases, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA; Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, USA. Electronic address: Jason.jiang@cchmc.org.
3
Division of Infectious Diseases, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA; Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, USA. Electronic address: Ming.Tan@cchmc.org.

Abstract

Rotaviruses cause severe diarrhea in infants and young children, leading to significant morbidity and mortality. Despite implementation of current rotavirus vaccines, severe diarrhea caused by rotaviruses still claims ∼200,000 lives of children with great economic loss worldwide each year. Thus, new prevention strategies with high efficacy are highly demanded. Recently, we have developed a polyvalent protein nanoparticle derived from norovirus VP1, the S particle, and applied it to display rotavirus neutralizing antigen VP8* as a vaccine candidate (S-VP8*) against rotavirus, which showed promise as a vaccine based on mouse immunization and in vitro neutralization studies. Here we further evaluated this S-VP8* nanoparticle vaccine in a mouse rotavirus challenge model. S-VP8* vaccines containing the murine rotavirus (EDIM strain) VP8* antigens (S-mVP8*) were constructed and immunized mice, resulting in high titers of anti-EDIM VP8* IgG. The S-mVP8* nanoparticle vaccine protected immunized mice against challenge of the homologous murine EDIM rotavirus at a high efficacy of 97% based on virus shedding reduction in stools compared with unimmunized controls. Our study further supports the polyvalent S-VP8* nanoparticles as a promising vaccine candidate against rotavirus and warrants further development.

KEYWORDS:

Nanoparticle; Norovirus; Rotavirus; S particle; Subunit vaccine; Subviral particle; Vaccine platform

PMID:
31201052
PMCID:
PMC6668625
[Available on 2020-07-09]
DOI:
10.1016/j.vaccine.2019.05.075

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center